본문 바로가기
KERD
논문KCI 등재

방사성요오드 치료저항성 갑상선암에서 방사성요오드 병용치료의 새로운 전략

New Strategies for Combined Radioiodine Therapy in Refractory Thyroid Cancer

정준기|팽진철|오소원
대한갑상선학회 (Korean Thyroid Association)|2015.05|International Journal of Thyroidology|제8권 제1호|pp. 26-35

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

방사성요오드RadioiodineMolecular targeted therapyRefractory thyroid cancer치료저항성 갑상선암재분화 치료분자표적 치료Redifferentiation therapy
주제분류의학일반

초록

The prognosis of differentiated thyroid cancer (DTC) is excellent, which is mainly due to the high therapeutic efficacy of radioactive iodine (RAI) therapy as well as indolent nature of thyroid cancer itself. Although most patients with DTC are well treated with RAI therapy, a certain number of patients have been suffered from refractoriness to RAI therapy. To overcome refractoriness, many alternative treatments have been investigated, and they could be classified based on the mechanisms of action; redifferentiation drug and molecular targeted drug. Not only redifferentiated drugs but also molecular targeted drugs could induce differentiation of thyroid cancer cells. Consequently, alternative treatments allowing tumor cells of RAI avidity followed by RAI therapy could utilize a synergistic effect of both therapies. Combined RAI therapy is expected to improve therapeutic effects and prognoses of RAI refractory thyroid cancers.

Abstract

The prognosis of differentiated thyroid cancer (DTC) is excellent, which is mainly due to the high therapeutic efficacy of radioactive iodine (RAI) therapy as well as indolent nature of thyroid cancer itself. Although most patients with DTC are well treated with RAI therapy, a certain number of patients have been suffered from refractoriness to RAI therapy. To overcome refractoriness, many alternative treatments have been investigated, and they could be classified based on the mechanisms of action; redifferentiation drug and molecular targeted drug. Not only redifferentiated drugs but also molecular targeted drugs could induce differentiation of thyroid cancer cells. Consequently, alternative treatments allowing tumor cells of RAI avidity followed by RAI therapy could utilize a synergistic effect of both therapies. Combined RAI therapy is expected to improve therapeutic effects and prognoses of RAI refractory thyroid cancers.

참고문헌 (53)

  1. 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010", Cancer Research and Treatment, 45(1), pp.1~14 (2013), 대한암학회[DOI]
  2. Machens A, "The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma", Cancer, 103(11), pp.2269~2273 (2005)
  3. Cho BY, "Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades", Thyroid, 23(7), pp.797~804 (2013)
  4. Fernandes JK, "Overview of the management of differentiated thyroid cancer", Curr Treat Options Oncol, 6(1), pp.47~57 (2005)
  5. Schlumberger M, "Management of refractory thyroid cancers", Ann Endocrinol (Paris), 72(2), pp.149~157 (2011)
  6. Chung JK, "Sodium iodide symporter: its role in nuclear medicine", J Nucl Med, 43(9), pp.1188~1200 (2002)
  7. Durante C, "Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma:benefits and limits of radioiodine therapy", J Clin Endocrinol Metab, 91(8), pp.2892~2899 (2006)
  8. Sherman SI, "Cytotoxic chemotherapy for differentiated thyroid carcinoma", Clin Oncol (R Coll Radiol), 22(6), pp.464~468 (2010)
  9. 팽진철, "Alternative Medical Treatment for Radioiodine-Refractory Thyroid Cancers", Nuclear Medicine and Molecular Imaging, 45(4), pp.241~247 (2011), 대한핵의학회
  10. Brose MS, "Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer", BMC Cancer, 11, pp.349~ (2011)
  11. Ho AL, "Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer", N Engl J Med, 368(7), pp.623~632 (2013)
  12. Altucci L, "The promise of retinoids to fight against cancer", Nat Rev Cancer, 1(3), pp.181~193 (2001)
  13. Schmutzler C, "The promoter of the human sodium", iodide-symporter gene responds to retinoic acid, 2002, pp.189(1-2), 145~155
  14. Jeong H, "Effect of all-trans retinoic acid on sodium", iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line, 2006, pp.33(7), 875~882
  15. Hoffmann S, "Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells", Mol Cell Endocrinol, 264(1-2), pp.74~81 (2007)
  16. Simon D, "Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid : basics and first clinical results", Exp Clin Endocrinol Diabetes, 104(Suppl 4), pp.13~15 (1996)
  17. Simon D, "Redifferentiation therapy with retinoids:therapeutic option for advanced follicular and papillary thyroid carcinoma", World J Surg, 22(6), pp.569~574 (1998)
  18. Grunwald F, "Redifferentiation therapy-induced radioiodine uptake in thyroid cancer", J Nucl Med, 39(11), pp.1903~1906 (1998)
  19. Simon D, "Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study", Eur J Nucl Med Mol Imaging, 29(6), pp.775~782 (2002)
  20. Chung JK, "Clinical significance of hepatic visualization on iodine-131whole-body scan in patients with thyroid carcinoma", J Nucl Med, 38(8), pp.1191~1195 (1997)
  21. Short SC, "A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer", Clin Oncol (R Coll Radiol), 16(8), pp.569~574 (2004)
  22. Courbon F, "Defective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinoma", Thyroid, 16(10), pp.1025~1031 (2006)
  23. Handkiewicz-Junak D, "13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropinaided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study", Thyroid Res, 2(1), pp.8~ (2009)
  24. Gruning T, "Retinoic acid for redifferentiation of thyroid cancer--does it hold its promise?", Eur J Endocrinol, 148(4), pp.395~402 (2003)
  25. Kim WG, "Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer", Endocr J, 56(1), pp.105~112 (2009)
  26. Fernandez CA, "Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake", J Endocrinol Invest, 32(3), pp.228~233 (2009)
  27. Oh SW, "Combined therapy with 131I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer", Eur J Nucl Med Mol Imaging, 38(10), pp.1798~1805 (2011)
  28. Xing M, "Molecular pathogenesis and mechanisms of thyroid cancer", Nat Rev Cancer, 13(3), pp.184~199 (2013)
  29. Kitazono M, "Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)", I(-)symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells, 2001, pp.86(7), 3430~3435
  30. Furuya F, "Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium", iodide symporter thyroperoxidase and thyroglobulin, 2004, pp.145(6), 2865~2875
  31. Zarnegar R, "Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor", Surgery, 132(6), pp.984~990 (2002)
  32. Fortunati N, "Valproic acid induces the expression of the Na+", I- symporter and iodine uptake in poorly differentiated thyroid cancer cells, 2004, pp.89(2), 1006~1009
  33. Puppin C, "Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors", Endocrinology, 146(9), pp.3967~3974 (2005)
  34. Kelly WK, "Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer", J Clin Oncol, 23(17), pp.3923~3931 (2005)
  35. Woyach JA, "Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma", J Clin Endocrinol Metab, 94(1), pp.164~170 (2009)
  36. Hou P, "Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways", J Clin Endocrinol Metab, 95(2), pp.820~828 (2010)
  37. "Science", 2000, 1357~1360
  38. Karger S, "Evaluation of peroxisome proliferator-activated receptor-gamma expression in benign and malignant thyroid pathologies", Thyroid, 15(9), pp.997~1003 (2005)
  39. Park JW, "Troglitazone, the peroxisome proliferatoractivated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines", Thyroid, 15(3), pp.222~231 (2005)
  40. Philips JC, "Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers", Nucl Med Commun, 25(12), pp.1183~1186 (2004)
  41. Kebebew E, "A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer", Surgery, 140(6), pp.960~967 (2006)
  42. Kebebew E, "Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer", Thyroid, 19(9), pp.953~956 (2009)
  43. Tepmongkol S, "Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma", Thyroid, 18(7), pp.697~704 (2008)
  44. Liu Z, "Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase", akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers, 2008, pp.93(8), 3106~3116
  45. Xing M, "BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer", J Clin Endocrinol Metab, 90(12), pp.6373~6379 (2005)
  46. Liu D, "Suppression of BRAF", MEK, Clin Cancer Res, pp.2007, 13(4)[DOI]
  47. Gupta-Abramson V, "Phase II trial of sorafenib in advanced thyroid cancer", J Clin Oncol, 26(29), pp.4714~4719 (2008)
  48. Kloos RT, "Phase II trial of sorafenib in metastatic thyroid cancer", J Clin Oncol, 27(10), pp.1675~1684 (2009)
  49. "Ann Oncol", 2008, 218~
  50. Hoftijzer H, "Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma", Eur J Endocrinol, 161(6), pp.923~931 (2009)
  51. Cohen EE, "Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study", J Clin Oncol, 26(29), pp.4708~4713 (2008)
  52. Sherman SI, "Motesanib diphosphate in progressive differentiated thyroid cancer", N Engl J Med, 359(1), pp.31~42 (2008)
  53. Bible KC, "Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers:results of a phase 2 consortium study", Lancet Oncol, 11(10), pp.962~972 (2010)

이 간행물의 다른 논문 (17건)

갑상선암과 방사선김종순pp. 1-7갑상선분화암의 수술 후 감시: 영상의학과의사의 관점곽진영pp. 8-13저용량 대 고용량 방사성요오드 치료원경숙pp. 14-18경액와 액와부 접근법 로봇 갑상선 수술 후 삶의 질 변화이잔디, 정웅윤pp. 19-25대한갑상선학회의 역사와 갑상선암진단과 치료에 대한 최근 논쟁에 관한 고찰이광우pp. 36-49
원문 보기